iOnctura and Yellowstone: Syncona’s Latest Cancer Biotech Acquisitions
TLDR: Syncona has added two cancer biotechs, iOnctura and Yellowstone, to its growing portfolio. iOnctura received 80 million euros in series B financing, with Syncona contributing 30 million euros. Syncona, a London-based